Literature DB >> 25534480

Substantia nigra neuromelanin magnetic resonance imaging in de novo Parkinson's disease patients.

S Reimão1, P Pita Lobo, D Neutel, L Correia Guedes, M Coelho, M M Rosa, J Ferreira, D Abreu, N Gonçalves, C Morgado, R G Nunes, J Campos, J J Ferreira.   

Abstract

BACKGROUND: Depigmentation of the substantia nigra (SN) and locus coeruleus (LC) is a conspicuous pathological feature of Parkinson's disease (PD) and is related to the loss of neuromelanin, whose paramagnetic properties result in high signal on specific T1-weighted magnetic resonance imaging (MRI). Recent studies have suggested that neuromelanin decrease in the SN and LC of PD patients may emerge as a possible diagnostic biomarker. The SN neuromelanin signal in de novo and early stage PD patients was studied to assess its diagnostic accuracy. This is the first study based on a semi-automated MRI analysis of the neuromelanin signal in de novo PD patients.
METHODS: The inclusion criteria were untreated de novo PD and a 2-5 year disease duration; in addition, age matched healthy controls were enrolled. These were studied with a high-resolution T1-weighted MRI sequence at 3 T to visualize neuromelanin. The primary outcome was SN high signal area, length and neuromelanin/midbrain ratio obtained with semi-automated methods.
RESULTS: A total of 12 de novo PD patients and 10 PD patients with a 2-5 year disease duration were evaluated. The area, length of the SN T1 high signal and the SN neuromelanin/midbrain ratio were markedly decreased in the PD groups compared with age-matched controls, with a substantial overlap between the two PD groups.
CONCLUSIONS: Neuromelanin-sensitive MRI techniques can discriminate PD patients from healthy individuals with high sensitivity and specificity. Our findings are consistent with recent findings showing that PD neuromelanin changes remain stable during the course of the disease.
© 2014 EAN.

Entities:  

Keywords:  Parkinson's disease; locus coeruleus; magnetic resonance imaging; neuromelanin; substantia nigra

Mesh:

Substances:

Year:  2014        PMID: 25534480     DOI: 10.1111/ene.12613

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  28 in total

1.  Reproducibility of locus coeruleus and substantia nigra imaging with neuromelanin sensitive MRI.

Authors:  Jason Langley; Daniel E Huddleston; Christine J Liu; Xiaoping Hu
Journal:  MAGMA       Date:  2016-09-29       Impact factor: 2.310

2.  Diagnostic performance of neuromelanin-sensitive magnetic resonance imaging for patients with Parkinson's disease and factor analysis for its heterogeneity: a systematic review and meta-analysis.

Authors:  Se Jin Cho; Yun Jung Bae; Jong-Min Kim; Donghyun Kim; Sung Hyun Baik; Leonard Sunwoo; Byung Se Choi; Jae Hyoung Kim
Journal:  Eur Radiol       Date:  2020-09-04       Impact factor: 5.315

3.  Neuromelanin MRI is useful for monitoring motor complications in Parkinson's and PARK2 disease.

Authors:  Taku Hatano; Ayami Okuzumi; Koji Kamagata; Kensuke Daida; Daisuke Taniguchi; Masaaki Hori; Hiroyo Yoshino; Shigeki Aoki; Nobutaka Hattori
Journal:  J Neural Transm (Vienna)       Date:  2017-02-03       Impact factor: 3.575

Review 4.  Magnetic resonance imaging for the diagnosis of Parkinson's disease.

Authors:  Beatrice Heim; Florian Krismer; Roberto De Marzi; Klaus Seppi
Journal:  J Neural Transm (Vienna)       Date:  2017-04-04       Impact factor: 3.575

Review 5.  α-Synuclein in Parkinson's disease: causal or bystander?

Authors:  Peter Riederer; Daniela Berg; Nicolas Casadei; Fubo Cheng; Joseph Classen; Christian Dresel; Wolfgang Jost; Rejko Krüger; Thomas Müller; Heinz Reichmann; Olaf Rieß; Alexander Storch; Sabrina Strobel; Thilo van Eimeren; Hans-Ullrich Völker; Jürgen Winkler; Konstanze F Winklhofer; Ullrich Wüllner; Friederike Zunke; Camelia-Maria Monoranu
Journal:  J Neural Transm (Vienna)       Date:  2019-06-25       Impact factor: 3.575

6.  Relationship between neuromelanin and dopamine terminals within the Parkinson's nigrostriatal system.

Authors:  Antonio Martín-Bastida; Nicholas P Lao-Kaim; Andreas Antonios Roussakis; Graham E Searle; Yue Xing; Roger N Gunn; Stefan T Schwarz; Roger A Barker; Dorothee P Auer; Paola Piccini
Journal:  Brain       Date:  2019-07-01       Impact factor: 13.501

7.  Diffusion tensor imaging of the substantia nigra in Parkinson's disease revisited.

Authors:  Jason Langley; Daniel E Huddleston; Michael Merritt; Xiangchuan Chen; Rebecca McMurray; Michael Silver; Stewart A Factor; Xiaoping Hu
Journal:  Hum Brain Mapp       Date:  2016-03-29       Impact factor: 5.038

8.  Multimodal assessment of nigrosomal degeneration in Parkinson's disease.

Authors:  Jason Langley; Daniel E Huddleston; Bruce Crosson; David D Song; Stewart A Factor; Xiaoping Hu
Journal:  Parkinsonism Relat Disord       Date:  2020-09-16       Impact factor: 4.891

9.  Pool size ratio of the substantia nigra in Parkinson's disease derived from two different quantitative magnetization transfer approaches.

Authors:  Paula Trujillo; Paul E Summers; Alex K Smith; Seth A Smith; Luca T Mainardi; Sergio Cerutti; Daniel O Claassen; Antonella Costa
Journal:  Neuroradiology       Date:  2017-10-06       Impact factor: 2.804

Review 10.  Nigrosome Imaging and Neuromelanin Sensitive MRI in Diagnostic Evaluation of Parkinsonism.

Authors:  Nicola Pavese; Yen F Tai
Journal:  Mov Disord Clin Pract       Date:  2018-02-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.